General Western Blot Reagents
Abcam beta-Elemene, Anticancer agent, 100MG
MW 204.35 Da. Anticancer agent. Induces G₂M cell cycle arrest and apoptosis. Induces caspase-3, -7 and -9 activities. Decreases Bcl-2 expression. Induces mitochondrial release of cytochrome c. Inhibits microtubule polymerization. Downregulates uPA, uPAR, MMP-2, and MMP-9 expression. Shows antiproliferative effects. Shows antitumor effects in vivo. .
The product is subject to the following: Abcam Restricted Use Statement
Abcam Asta x anthin, Antio x idant agent, 5MG
MW 596.8 Da, Purity >97%. Potent antioxidant agent. PPARα agonist and PPARγ antagonist. Free radical scavenger. Reduces oxidative stress. Induces apoptosis. Inhibits NF-κB. Shows anti-inflammatory, antihypertensive, cardioprotective, neuroprotective and antitumor effects in vivo. Orally active.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Nocardamine (Deferrio x amine E), Antibiotic agent, 1MG
MW 600.7 Da, Purity >95%. Antibiotic agent. Siderophore iron chelator. Induces morphological changes in insect cells. Shows weak antimicrobial against Gram-positive bacteria.
The product is subject to the following: Abcam Restricted Use Statement
Abcam CAY10585, HIF-1alpha inhibitor, 25MG
MW 435.5 Da, Purity >97%. HIF-1α inhibitor (IC₅₀ values are 2.6 and 0.7 μM for Hep3B and AGS cell lines respectively). Suppresses transcription of HIF-1 target genes VEGF and erythropoietin at 10 μM. Attenuates hypoxia-induced ANP secretion. Blunts BMP9-induced osteogenic signaling in MSCs.
The product is subject to the following: Abcam Restricted Use Statement
Abcam VAS 2870, NADPH o x idase inhibitor, 10MG
MW 360.4 g/mol, Purity >98%. NADPH oxidase inhibitor. Blocks PDGF-mediated NADPH activation and ROS production. Inhibits PMS-induced oxidative burst (IC₅₀ = 2 μM, HeLa cells). Shows anti-ischemic effects ex vivo. .
The product is subject to the following: Abcam Restricted Use Statement
Abcam Resorufin butyrate, Fluorogenic lipase and cholinesterase substrate, 25MG
MW 283.28 Da, Purity >95%. Fluorogenic lipase and cholinesterase substrate. Fluoresces on hydrolysis. Resorufin methyl ether (ab145372) analog.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Trichostatin A, histone deacetylase inhibitor, 1MG
MW 302.37 Da, Purity >98%. Potent, selective histone deacetylase (HDAC) inhibitor (Ki = 3.4 nM). Induces cell proliferation, differentiation and apoptosis in vitro. Anticancer and antifungal agent. Active in vivo and in vitro.
The product is subject to the following: Abcam Restricted Use Statement
Abcam N-Oleoylethanolamine, PPAR-alpha agonist, 100MG
MW 325.5 Da, Purity >98%. Potent PPAR-α agonist (EC₅₀ = 120 nM). Anandamide (ab120087, ab120429) analog. Binds to cannabinoid receptor GPR119. Shows anti-ischemic and neuroprotective effects in vivo. Orally active.
The product is subject to the following: Abcam Restricted Use Statement
Abcam AMI 1, protein arginine methyltransferase inhibitor, 25MG
MW 548.5 Da, Purity =99%. Potent, selective and reversible protein arginine methyltransferase inhibitor (IC₅₀ = 1.63 μM). ROS° scavenger with antioxidant effects (IC₅₀ = 8.3 μM). Inhibits arginine in vitro without competing for the AdoMet binding site. Modulates nuclear receptor-regulated transcription in vivo. Cell-permeable.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Sulprostone, EP1/ EP3 receptor agonist, 5MG
MW 465.65 g/mol, Purity >98%. Selective EP₁/ EP₃ receptor agonist (Ki values are 21 and 0.6 nM, respectively). PGE₂ analog.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Indo-1 AM, fluorescent Ca2+ indicator, 1MG
MW 1009.9 Da, Purity >95%. Cell-permeable, ratiometric, fluorescent Ca2+ indicator. Binds to Ca2+ with high affinity (Kd = 230 nM). Fluoresces blue/violet and fluorescence increases upon Ca2+ binding. Cell-impermeable form, Indo 1 K+ salt (ab142779) also available. Emission and excitation shifts from 475 to 401 nm and 346 to 330 nm respectively depending on Ca2+ binding.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Human Histone H3 (tri methyl K4) peptide, 1MG
Human Histone H3 (tri methyl K4) peptide is a Synthetic blocking peptide. >90% purity and suitable for Dot, BL.
Protein/ Peptide/ Enzyme Synonyms: H3FA, HIST1H3A, H3C2, H3FL, HIST1H3B, H3C3, H3FC HIST1H3C, H3C4, H3FB, HIST1H3D, H3C6, H3FD, HIST1H3E, H3C7, H3FI, HIST1H3F, H3C8, H3FH, HIST1H3G, H3C10, H3FK, HIST1H3H, H3C11, H3FF, HIST1H3I, H3C12, H3FJ, HIST1H3J, H3C1, HIST1H3C, H3FC, Histone H3.1, Histone H3/a, Histone H3/b, Histone H3/c, Histone H3/d, Histone H3/f, Histone H3/h, Histone H3/i, Histone H3/j, Histone H3/k, Histone H3/l, H3K4me3
Conjugation: Unconjugated
The product is subject to the following: Abcam Restricted Use Statement
Abcam Clindamycin, inhibits protein synthesis, 50MG
MW 425 Da, Purity >99%. Broad spectrum antimicrobial agent. Active against Gram-positive and Gram-negative bacteria and selected protozoa. Competitive inhibitor of peptide formation in large 50S ribosomal unit. Orally active in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam BML-210, HDAC inhibitor, 5MG
MW 339.4 Da, Purity >98%. Histone deacetylase (HDAC) inhibitor (IC₅₀ = 87 μM). Induces changes in gene expression profile. Antiproliferative activity in vitro.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Troglitazone, PPAR-gamma receptor agonist, 10MG
MW 441.5 Da, Purity >97%. Potent, selective PPAR-γ receptor agonist (EC₅₀ = 780 nM). No activity at PPAR-α or PPAR-δ (up to 10 mM). Orally active. Antidiabetic and anticancer agent. Active in vivo and in vitro.
The product is subject to the following: Abcam Restricted Use Statement